Objectives: Shiga toxin-producing Escherichia coli (STEC) are zoonotic and transmission to humans occurs via contaminated food or contact with infected animals. In this study, WGS data were used to predict antimicrobial resistance (AMR) in STEC from symptomatic human cases to assess the extent of transmission of antibioticresistant E. coli from animals to humans.
Introduction
Antimicrobial resistance (AMR) in foodborne pathogens can be a consequence of the use of antimicrobial drugs in food-producing animals. Most livestock species carry Escherichia coli asymptomatically in their intestine and this bacterium is often used as a commensal indicator of AMR in Gram-negative bacteria, alongside monitoring of resistance in pathogens, such as Salmonella and Campylobacter. 1 Strains of E. coli often acquire conjugative plasmids carrying resistance genes, which facilitate the spread of AMR to other enteric bacteria. 1, 2 Over recent decades, there has been a gradual increase in the proportion of strains of extraintestinal pathogenic E. coli (ExPEC) isolated from humans that are resistant to cefotaxime, ceftazidime, ciprofloxacin and gentamicin. 3 Although resistant strains of E. coli have been isolated from non-human sources, and despite many ongoing surveillance projects and the recent focus on the veterinary and clinical 'One Health' aspects of AMR, evidence of the extent of any public health risk posed by animal reservoirs with respect to the transmission of resistant strains of E. coli to humans remains varied and contentious. In contrast to ExPEC, Shiga toxin-producing Escherichia coli (STEC) represent a population of gastrointestinal human pathogens of zoonotic origin. The natural reservoir of STEC is the gastrointestinal tract of ruminant animals, particularly cattle. 4 Human infection can occur via contaminated foods, beverages or water, or direct contact with infected animals or their environment. 5 Monitoring AMR in STEC from symptomatic human cases may provide evidence for the extent of transmission of resistant strains and resistance genes from ruminants to humans. In England, the most common STEC serogroup associated with human disease is O157, with around 900 cases reported each year. 5 Presumptive STEC O157 isolated at local or regional hospital laboratories from faecal specimens taken from cases with symptoms of gastrointestinal disease and/or haemolytic uraemic syndrome (HUS) are submitted to the Gastrointestinal Bacteria Reference Unit (GBRU) at PHE. The most common STEC non-O157 serogroup isolated from faecal specimens submitted to GBRU for culture is STEC O26. 6, 7 Until recently, AMR determination for STEC was not routinely performed at GBRU, partly because antimicrobial therapy is not clinically indicated for this pathogen, but mainly due to limited resources and logistical difficulties associated with performing AMR testing at Containment Level III. Consequently, AMR profiles for isolates of domestically acquired or travel-related STEC in England were unknown.
In June 2015, GBRU implemented WGS as the routine method of surveillance for STEC. 8, 9 Known genotypes associated with mechanisms of AMR can be detected and the phenotypic AMR profile can be inferred. Previous studies have shown a high concordance between phenotypic and WGS predicted antimicrobial susceptibility for other E. coli pathotypes. 10 -12 The aim of this study was to investigate AMR in isolates of STEC serogroups O157 and O26 using WGS data, in order to understand the extent to which antibiotic-resistant E. coli are transferred to humans as zoonotic pathogens, and also to define the diversity of resistance genes that STEC strains may introduce into the human gut.
Methods

Bacterial isolates, identification and susceptibility testing
All isolates of STEC O157 (n ¼ 396) and STEC O26 (n ¼ 34) submitted to GBRU for confirmation and typing between June 2015 and January 2016 were included in this study. The isolates were from 430 different patients reporting to general practitioners or local hospital accident and emergency departments with symptoms of gastrointestinal disease and/or HUS. The STEC O157 isolates belonged to all three STEC O157 lineages (lineages I, I/II and II) and comprised 17 different phage types. 13 Travel histories were available from enhanced surveillance questionnaires administered to each case and recorded in the National Enhanced Surveillance System for STEC. 5 
WGS
Genomic DNA was extracted, fragmented and tagged for multiplexing with Nextera XT DNA Sample Preparation Kits, followed by paired-end sequencing on an Illumina HiSeq platform to produce 100 bp short read sequence fragments (Illumina, Cambridge, UK). Antimicrobial resistance determinants were sought using 'Genefinder', a customized algorithm that uses Bowtie 2 14 to map reads to a set of reference sequences and Samtools to generate an mpileup file (M. Doumith, PHE, unpublished results). The data are parsed based on read coverage (100%), base-call variation (.85%) and nucleotide identity (.90%) to determine the presence of the reference sequence or nucleotide variation within that sequence. Known acquired resistance genes and resistance-conferring mutations relevant to carbapenems, other b-lactams, fluoroquinolones, aminoglycosides, chloramphenicol, macrolides, sulphonamides, tetracyclines, trimethoprim, rifamycins and fosfomycin were included in the analysis. FASTQ sequences were deposited in the National Center for Biotechnology Information Short Read Archive under the BioProject PRJNA315192.
Antimicrobial susceptibility testing
Susceptibility testing was performed on all viable isolates exhibiting resistance to at least one antimicrobial and four isolates predicted from the WGS data to have a fully susceptible phenotype (n ¼ 78) (Table S1, 
Statistical analysis
Comparisons were made between the AMR profiles associated with cases who reported travel abroad in the 7 days prior to onset of symptoms and those associated with cases who did not report recent travel. Fisher's exact test was used to assess statistical significance. A P value of ≤0.05 was deemed statistically significant. All statistical analyses were performed using STATA 12.0 (Stata Corporation).
Results
Resistance to b-lactams
Of the 430 isolates in this study, 59 (13.7%) had genes predicted to confer resistance to ampicillin, including 49 (12.4%) STEC O157 and 10 (29.4%) STEC O26 (Table 1 and Table S1 ). Specifically, the genes detected encoded the penicillinases TEM-1 (n ¼ 51), TEM-191 (n ¼ 3), TEM-117 (n ¼ 1), TEM-122 (n ¼ 1) and OXA-1 (n ¼ 1), and the ESBLs CTX-M-3 (n ¼ 1) and CTX-M-15 (n ¼ 2) (Table 1) . Seventy-eight isolates (55 with an ampicillin-resistant genotype and 23 with a predicted susceptible genotype) were tested for phenotypic ampicillin resistance, with complete correlation between genotype and phenotype ( Table 2 and Table S1 ). All three CTX-M-positive isolates showed phenotypic resistance to the third-generation cephalosporins. Carbapenemase genes were not detected in any of the 430 isolates.
Resistance to quinolones
Ten STEC O157 isolates (2.3%) had the gyrA 83:S-L mutation and/ or harboured a plasmid-mediated quinolone resistance (PMQR) gene (qnrS1); no parC mutations were detected (Table 1) . Of these, nine were tested and confirmed phenotypically to express resistance to nalidixic acid and reduced susceptibility to ciprofloxacin (MIC .0.064, ,0.5 mg/L) ( Table 2 and Table S1 ). By contrast, 68/69 isolates that were confirmed to be phenotypically susceptible to the quinolones lacked any mutations in the quinolone resistance-determining regions of gyrA and parC and had no known PMQR determinants. The one exception was an isolate Day et al. that had a rare mutation in gyrA (100:Y-C), but did not exhibit decreased susceptibility to ciprofloxacin (Table 2 ).
Resistance to phenicols
Nine isolates (2.1%) had either floR (n ¼ 8) or catA1 (n ¼ 1), predicted to confer chloramphenicol resistance, including five (1.3%) STEC O157 and four (11.8%) STEC O26 (Table 1 and  Table S1 ). Phenotypic resistance to chloramphenicol was confirmed in the eight isolates tested (MIC .16 mg/L) ( Table 2 and  Table S1 ). Seventy isolates that were predicted genotypically to be susceptible to chloramphenicol were also found susceptible phenotypically ( Table 2 and Table S1 ).
Resistance to sulphonamides
Sixty-eight (15.8%) isolates had genes expected to confer sulphonamide resistance, including 57 (14.4%) STEC O157 and 11 (32.4%) STEC O26. Of these, 1 had sul1, 54 had sul2 and 13 had both sul1 and sul2 (Table 1 and Table S1 ). Sixty-one isolates with a sulphonamide-resistant genotype and 17 with a susceptible genotype were tested for phenotypic resistance; all isolates matched the predicted phenotype derived from the WGS data (Table 2 and Table S1 ).
Resistance to trimethoprim
Thirty-four (7.9%) isolates had dfrA genes (dfrA1 ¼ 13; dfrA7 ¼ 6; dfrA8 ¼ 14; dfrA14 ¼ 1), conferring resistance to trimethoprim, including 30 (7.6%) STEC O157 and 4 (11.8%) STEC O26 (Table 1  and Table S1 ). Thirty-one isolates with a trimethoprim-resistant genotype and 47 with a susceptible genotype were tested for phenotypic resistance; all isolates matched the predicted phenotype derived from the WGS data (Table 2 and Table S1 ).
Resistance to tetracyclines
Fifty-seven (13.3%) isolates had tet(A), predicted to confer tetracycline resistance, including 51 (12.9%) STEC O157 and 6 (17.6%) STEC O26 (Table 1) . Fifty-one isolates with a tetracycline-resistant genotype and 27 isolates with a susceptible genotype were tested phenotypically and all isolates matched the predicted phenotype derived from the WGS data (Table 2 and Table S1 ). AMR in STEC serogroups O157 and O26
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Resistance to aminoglycosides Seventy (16.3%) isolates had genes expected to confer streptomycin resistance, including 60 (15.2%) STEC O157 and 10 (29.4%) STEC O26. Sixty-two (14.4%) had strA-strB only, three had aadA variants without strA-strB and one had aadA1 and strA-strB (Table 1  and Table S1 ). Of the three harbouring aadA only, two had both aadA2 and aadA17 variants and one had aadA1. Four had strA
and aadD [aph(4)-Ia] (associated with resistance to streptomycin) and aac(3)-IVa, which confers resistance to a broad range of aminoglycosides, including gentamicin and the veterinary aminoglycoside, apramycin (Table 1) . Sixty-three isolates with a streptomycin-resistant genotype and 15 isolates with a susceptible genotype were tested phenotypically and all isolates matched the predicted phenotype derived from the WGS data (Table 2 and Table S1 ). Three of the four isolates that had aac(3)-IVa were tested phenotypically and all were resistant to gentamicin.
Resistance to macrolides
Genes predicted to be associated with macrolide resistance were found in 10 isolates: 9 (2.3%) STEC O157 and 1 (2.9%) STEC O26. Eight were genes expected to confer resistance to azithromycin [mph(A) ¼ 1; mph(B) ¼ 7] and two were lnu(F), potentially associated with resistance to lincosamides ( Table 1) . Genotypic resistance to azithromycin was confirmed phenotypically in the isolate carrying mph(A) (MIC ¼ 64 mg/L), whereas the six isolates harbouring mph(B) that were phenotypically tested exhibited a lowlevel increase in azithromycin (MIC 1-2 mg/L) ( Table 2) . Phenotypic testing for lincosamide resistance was not available.
Resistance to rifamycins and fosfomycin
None of the isolates in this study was predicted to be resistant to the rifamycins or fosfomycin.
AMR profiles and multidrug resistance
Three hundred and forty-nine (81.2%) STEC isolates in this study were fully susceptible to all tested antibiotic classes. For STEC O157, 69/396 (17.4%) isolates were resistant to at least one antimicrobial, as were 12/34 (35.3%) STEC O26 isolates. Of the 396 STEC O157 isolates in this study, 60 (15.2%) STEC O157 and 9 (26.5%) of the 34 STEC O26 isolates were MDR (resistant to three or more classes of antimicrobials) ( Table 3) . 15 Among the 81 resistant isolates, the most common genotypic resistance profiles were: (i) bla TEM-1 , strA-strB, sul1 and/or sul2, dfrA and tet(A) (22 isolates; 5.1% of STEC overall); (ii) strA-strB, sul1 and/or sul2 and tet(A) (13 isolates; 3.0% overall); and (iii) bla TEM-1 , strA-strB, sul1 and/or sul2 and tet(A) (11 isolates; 2.6% overall) ( Table 3) .
Association between AMR and travel abroad
Of the 430 STEC cases included in this study, 150 (34.9%) reported travel abroad in the 7 days prior to onset of symptoms and 280 (65.1%) did not report recent travel. Eight of the 10 patients with STEC exhibiting low-level resistance to ciprofloxacin (MIC .0.064, ,0.5 mg/L) reported recent travel (Turkey n ¼ 3, Bangladesh n ¼ 1, mainland Europe n ¼ 1, India n ¼ 1, Mexico n¼ 1 and Spain n¼ 1). Six of nine patients with chloramphenicolresistant STEC reported recent travel (Turkey n¼ 2, Belgium n¼ 1, Morocco n¼ 1, Portugal n¼ 1 and Spain n¼ 1). The case infected with the isolate exhibiting phenotypic resistance to azithromycin reported recent travel to Bangladesh and cases harbouring mph(B) or lnu(F) had travelled to Spain (n ¼ 4), Belgium (n ¼ 1) and Turkey (n¼ 1). The proportion of isolates resistant to at least one antimicrobial or resistant to b-lactams, aminoglycosides, fluoroquinolones, tetracyclines, sulphonamides or macrolides was significantly higher in isolates from cases reporting foreign travel (Table 4 ).
Discussion
Our analysis of AMR in STEC serogroups O157 and O26 isolated between June 2015 and January 2016 revealed that 82.6% and 64.7% of isolates, respectively, were predicted to be fully susceptible to 11 different classes of antimicrobials. A Canadian study showed 62% of clinical isolates of STEC O157 were fully susceptible to all tested antibiotics. 16 The most commonly detected AMR profile in the study by Vidovic et al. 16 (2013) was for streptomycin, sulphonamide and tetracycline, and resistance to these three classes of antimicrobial, with or without resistance to ampicillin and trimethoprim, was common in this study (Table 3 ). Other studies have also reported high levels of resistance to these three antimicrobials in STEC O157. 17 -21 Krüger et al. 22 (2015) reported 17% of STEC O26 carried more than two antimicrobial resistance genes, with bla TEM-1 , strA-strB and sul2 being the most frequently detected.
An analysis of AMR in STEC O157 isolated from patients resident in England and Wales between 1995 and 1998 showed that 20% were resistant to one or more antimicrobials. 23 Variation in AMR profiles was limited, with 87% of the resistant strains exhibiting Day et al. Table 3 . (2) 24 (6.1) AMR in STEC serogroups O157 and O26 JAC resistance to streptomycin, sulphonamides and tetracyclines. 23, 24 In 1997, Threlfall et al. 24 (2000) showed that 16.7% of STEC O157 were resistant to streptomycin, sulphonamides and tetracyclines. A comparison of the historical data with data from this study indicated that there has been no increase in the incidence of resistance to these three antimicrobials over the last two decades. Resistance to ampicillin (12.4%) and chloramphenicol (1.3%), and reduced susceptibility to ciprofloxacin (2.3%), has increased since 1997. 24 Of further concern, three isolates were identified as ESBL producers. Strains of STEC harbouring bla CTX-M-3 or bla CTX-M-15 have been described previously in studies conducted in France, Germany and Egypt. 25 -27 Valat et al. 25 (2012) described a veterinary isolate from a calf in France, and the strain studied in Germany was from fenugreek seeds imported from Egypt. 26 A subsequent Egyptian study on AMR in food identified multidrug resistance (phenotypically resistant to ≥3 classes of antimicrobial) in 31/54 (57.4%) of STEC O157 isolated from 1600 food samples. 27 A study of E. coli (STEC¼ 23 and stx-negative E. coli ¼ 830) isolated from animals (mainly cattle, sheep, pigs and goats) between 2005 and 2007 showed that the highest levels of resistance were observed to ampicillin, streptomycin, sulphonamides and tetracyclines, with 39.1% of STEC and 38.1% of stx-negative E. coli expressing this profile.
1 This is consistent with the fact that tetracyclines, b-lactams and trimethoprim/sulphonamides account for the majority of therapeutic antimicrobials sold for veterinary use, 1 and with the observation that class 1 integrons, which are common in E. coli, frequently carry resistance to sulphonamides as well as other resistance genes. 1, 17, 20 The commonality of the AMR profiles in STEC and stx-negative E. coli isolates from animals in England with those from human STEC O157 cases indicated that the use of antimicrobial drugs in food-producing animals may be a risk factor for the presence of AMR in domestically acquired human clinical isolates of STEC O157.
Cheney et al.
1 reported no evidence of resistance to ciprofloxacin or the presence of ESBLs in the STEC isolates in their study, although 3.1% of non-STEC isolates were resistant to cefotaxime. Amikacin, gentamicin, cefotaxime, nalidixic acid and ciprofloxacin are not authorized for use in food-producing animals in England and Wales, although other aminoglycosides, third-generation cephalosporins and fluoroquinolones are authorized. Isolates that were resistant to ampicillin, streptomycin, sulphonamide, tetracycline and azithromycin and had reduced susceptibility to ciprofloxacin were associated with cases who reported recent travel abroad. Azithromycin and the fluoroquinolones are commonly used for the empirical treatment of travellers' diarrhoea. It is not clear whether the development of AMR in these strains was driven by over-prescribing by medical practitioners or by the use of these antimicrobials in veterinary practice in the country of origin.
Antimicrobial resistance is a global public health problem and growing scientific evidence indicates that it is impacted by both human and veterinary antimicrobial usage. 27, 28 Many countries, including the UK, have developed strategies for monitoring resistance in bacteria from farm animals and for promoting responsible use of antimicrobials by farmers. 1 The observation that the incidence of resistance to streptomycin, the sulphonamides and tetracycline in STEC O157 has not increased over the last 20 years may provide evidence of the success of that policy. However, the similarity in AMR profiles seen in E. coli isolated from ruminants and domestically acquired human clinical STEC indicates that meat products, or produce grown in an environment contaminated with zoonotic E. coli, remain an important vehicle for dissemination of antimicrobial-resistant E. coli. 27, 29, 30 Reassuringly, in this study no isolates were predicted to have highlevel ciprofloxacin resistance-mediated by combinations of mutations in gyrA and parC-or resistance to colistin, mediated either by chromosomal mutations or by the mcr-1 gene, which has recently been reported in China, the UK and elsewhere from human isolates and animal isolates. 31 -33 In this study, foreign travel was identified as a significant risk of acquiring MDR STEC; however, there were no isolates carrying carbapenem resistance genes.
The implementation of high-throughput WGS for all isolates of STEC for routine public health surveillance has enabled us to assess AMR in this group of pathogens for the first time since 1998, as this approach to routine AMR surveillance requires no extra laboratory testing. However, WGS data for determining AMR require careful analysis, as the results may be difficult to interpret in terms of phenotypic expression. For example, the gyrA mutation 100:Y-C was present in the quinolone resistancedetermining region of gyrA of one isolate in this study, but did not confer phenotypic resistance to ciprofloxacin. 34 Of more concern is the risk of missing a novel resistance mechanism not currently included in the reference database, which would result in predicting susceptibility in a resistant isolate. For STEC infection, antimicrobial therapy is not recommended, 35 -37 so the immediate clinical impact would be limited. However, this is a concern where WGS data are used to predict emerging AMR and to determine resistance or susceptibility in bacterial pathogens causing other infections where treatment is required. Recently, EUCAST concluded that available published evidence does not currently support use of WGS-inferred susceptibility to guide clinical decision making. However, the committee acknowledged that this approach may replace phenotypic testing for surveillance purposes in the near Day et al.
future
(http://www.eucast.org/fileadmin/src/media/PDFs/ EUCAST_files/Consultation/2016/ EUCAST_WGS_report_consultation_20160511.pdf). In this study, none of the 78 isolates tested phenotypically was genotypically susceptible/phenotypically resistant to the 11 classes of antimicrobials tested. Regular updating of the database to include novel AMR genes and mutations, and ongoing phenotypic testing of a sub-set of 'genotypically susceptible' isolates, will be required to ensure that the sensitivity of AMR profiles derived from WGS data remains high.
Public health surveillance of AMR in foodborne bacteria, including STEC, is essential. Resistant strains of gastrointestinal pathogens may have a selective advantage over other bacteria in intestines of humans or animals undergoing antibiotic treatments. 17, 38 Strains of E. coli often carry resistance genes on mobile genetic elements, facilitating the spread of AMR to other enteric bacteria.
1,2 Further work on other important STEC serotypes is needed to understand the full extent of the spectrum of AMR in the food chain. The implementation of WGS for the routine public health surveillance of STEC will enable PHE to monitor trends in AMR gene content and emerging resistances of this clinically significant zoonotic pathogen, and to provide real-time data on the prevalence of AMR in the food-chain and in travellers returning from abroad. 
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